ID   HASP_HUMAN              Reviewed;         798 AA.
AC   Q8TF76; Q5U5K3; Q96MN1; Q9BXS7;
DT   01-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   12-OCT-2022, entry version 183.
DE   RecName: Full=Serine/threonine-protein kinase haspin;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:19918049, ECO:0000269|PubMed:19918057};
DE   AltName: Full=Germ cell-specific gene 2 protein;
DE   AltName: Full=H-haspin;
DE   AltName: Full=Haploid germ cell-specific nuclear protein kinase;
GN   Name=HASPIN {ECO:0000312|HGNC:HGNC:19682};
GN   Synonyms=GSG2 {ECO:0000312|HGNC:HGNC:19682};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND CHROMOSOMAL LOCATION.
RC   TISSUE=Testis;
RX   PubMed=11228240; DOI=10.1093/molehr/7.3.211;
RA   Tanaka H., Iguchi N., Nakamura Y., Kohroki J., de Carvalho C.E.,
RA   Nishimune Y.;
RT   "Cloning and characterization of human haspin gene encoding haploid germ
RT   cell-specific nuclear protein kinase.";
RL   Mol. Hum. Reprod. 7:211-218(2001).
RN   [2]
RP   SEQUENCE REVISION TO 204; 328 AND 378.
RA   Tanaka H.;
RL   Submitted (NOV-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS
RP   CYS-82; ASP-204; THR-328 AND ALA-378.
RC   TISSUE=Testis {ECO:0000312|EMBL:AAK30300.1};
RX   PubMed=11311556; DOI=10.1016/s0378-1119(01)00387-0;
RA   Higgins J.M.G.;
RT   "The Haspin gene: location in an intron of the Integrin Alpha-E gene,
RT   associated transcription of an Integrin alpha-E-derived RNA and expression
RT   in diploid as well as haploid cells.";
RL   Gene 267:55-69(2001).
RN   [4] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT CYS-82.
RC   TISSUE=Peripheral blood {ECO:0000269|PubMed:14702039};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS CYS-82;
RP   ASP-204; THR-328 AND ALA-378.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H3, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=15681610; DOI=10.1101/gad.1267105;
RA   Dai J., Sultan S., Taylor S.S., Higgins J.M.G.;
RT   "The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation
RT   and normal metaphase chromosome alignment.";
RL   Genes Dev. 19:472-488(2005).
RN   [8]
RP   FUNCTION IN CHROMOSOME COHESION.
RX   PubMed=17084365; DOI=10.1016/j.devcel.2006.09.018;
RA   Dai J., Sullivan B.A., Higgins J.M.;
RT   "Regulation of mitotic chromosome cohesion by Haspin and Aurora B.";
RL   Dev. Cell 11:741-750(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-93; THR-97 AND SER-147, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-58, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   FUNCTION.
RX   PubMed=20705812; DOI=10.1126/science.1189435;
RA   Wang F., Dai J., Daum J.R., Niedzialkowska E., Banerjee B.,
RA   Stukenberg P.T., Gorbsky G.J., Higgins J.M.;
RT   "Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at
RT   centromeres in mitosis.";
RL   Science 330:231-235(2010).
RN   [12]
RP   FUNCTION.
RX   PubMed=20929775; DOI=10.1126/science.1194498;
RA   Yamagishi Y., Honda T., Tanno Y., Watanabe Y.;
RT   "Two histone marks establish the inner centromere and chromosome bi-
RT   orientation.";
RL   Science 330:239-243(2010).
RN   [13]
RP   PHOSPHORYLATION AT SER-93 AND SER-143 BY AURKB, ACTIVITY REGULATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21658950; DOI=10.1016/j.cub.2011.05.016;
RA   Wang F., Ulyanova N.P., van der Waal M.S., Patnaik D., Lens S.M.,
RA   Higgins J.M.;
RT   "A positive feedback loop involving Haspin and Aurora B promotes CPC
RT   accumulation at centromeres in mitosis.";
RL   Curr. Biol. 21:1061-1069(2011).
RN   [14]
RP   ACTIVITY REGULATION.
RX   PubMed=21804608; DOI=10.1038/onc.2011.335;
RA   Huertas D., Soler M., Moreto J., Villanueva A., Martinez A., Vidal A.,
RA   Charlton M., Moffat D., Patel S., McDermott J., Owen J., Brotherton D.,
RA   Krige D., Cuthill S., Esteller M.;
RT   "Antitumor activity of a small-molecule inhibitor of the histone kinase
RT   Haspin.";
RL   Oncogene 31:1408-1418(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 465-798 IN COMPLEX WITH AMP AND
RP   INHIBITOR IODOTUBERCIDIN, COFACTOR, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF LYS-511 AND HIS-651.
RX   PubMed=19918057; DOI=10.1073/pnas.0901989106;
RA   Eswaran J., Patnaik D., Filippakopoulos P., Wang F., Stein R.L.,
RA   Murray J.W., Higgins J.M., Knapp S.;
RT   "Structure and functional characterization of the atypical human kinase
RT   haspin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:20198-20203(2009).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 452-798, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF GLU-492; HIS-651; ASP-707; ASP-709; GLY-713 AND ASP-716.
RX   PubMed=19918049; DOI=10.1073/pnas.0908485106;
RA   Villa F., Capasso P., Tortorici M., Forneris F., de Marco A., Mattevi A.,
RA   Musacchio A.;
RT   "Crystal structure of the catalytic domain of Haspin, an atypical kinase
RT   implicated in chromatin organization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:20204-20209(2009).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-76; CYS-82; HIS-145; ASP-204; SER-283;
RP   LEU-301; THR-328; ALA-378 AND VAL-706.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that phosphorylates histone
CC       H3 at 'Thr-3' (H3T3ph) during mitosis. May act through H3T3ph to both
CC       position and modulate activation of AURKB and other components of the
CC       chromosomal passenger complex (CPC) at centromeres to ensure proper
CC       chromatid cohesion, metaphase alignment and normal progression through
CC       the cell cycle. {ECO:0000269|PubMed:11228240,
CC       ECO:0000269|PubMed:15681610, ECO:0000269|PubMed:17084365,
CC       ECO:0000269|PubMed:20705812, ECO:0000269|PubMed:20929775}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:19918049, ECO:0000269|PubMed:19918057};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:19918049,
CC         ECO:0000269|PubMed:19918057};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11228240, ECO:0000269|PubMed:19918057};
CC   -!- ACTIVITY REGULATION: Constitutive activity that does not require
CC       phosphorylation. Specifically inhibited by 3-(1H-indazol-5-yl)-N-
CC       propylimidazo[1,2-b]pyridazin-6-amine (CHR-6494).
CC       {ECO:0000269|PubMed:19918057, ECO:0000269|PubMed:21658950,
CC       ECO:0000269|PubMed:21804608}.
CC   -!- INTERACTION:
CC       Q8TF76; O75031: HSF2BP; NbExp=3; IntAct=EBI-1237328, EBI-7116203;
CC       Q8TF76; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1237328, EBI-352572;
CC       Q8TF76; Q99750: MDFI; NbExp=3; IntAct=EBI-1237328, EBI-724076;
CC       Q8TF76-1; P84228: H3c7; Xeno; NbExp=3; IntAct=EBI-15815652, EBI-2658213;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15681610}. Chromosome
CC       {ECO:0000269|PubMed:15681610}. Cytoplasm, cytoskeleton, spindle
CC       {ECO:0000269|PubMed:15681610}. Note=Nuclear during interphase and
CC       associates with the chromosomes and spindle apparatus during mitosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1 {ECO:0000269|PubMed:11228240, ECO:0000269|PubMed:11311556};
CC         IsoId=Q8TF76-1; Sequence=Displayed;
CC       Name=2 {ECO:0000303|PubMed:14702039};
CC         IsoId=Q8TF76-2; Sequence=VSP_050671, VSP_050672;
CC   -!- TISSUE SPECIFICITY: Strongly expressed in testis. Also present in
CC       thymus and bone marrow and low levels observed in prostate, intestine,
CC       lung, spleen and lymph node. Expressed in fetal skin, liver, kidney and
CC       small intestine and also in proliferating but not non-proliferating
CC       cell lines. {ECO:0000269|PubMed:11228240, ECO:0000269|PubMed:11311556}.
CC   -!- PTM: Autophosphorylated on both serine and threonine residues (By
CC       similarity). Strongly phosphorylated during mitosis but this does not
CC       appear to significantly affect its intrinsic kinase activity.
CC       Phosphorylation by AURKB is required for full activity toward histone
CC       H3 at 'Ser-3' in mitosis. {ECO:0000250, ECO:0000269|PubMed:15681610,
CC       ECO:0000269|PubMed:21658950}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. Haspin subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB039834; BAB21938.3; -; mRNA.
DR   EMBL; AF289865; AAK30300.1; -; mRNA.
DR   EMBL; AK056691; BAB71255.1; -; mRNA.
DR   EMBL; AC116914; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC047457; AAH47457.1; -; mRNA.
DR   CCDS; CCDS11036.1; -. [Q8TF76-1]
DR   RefSeq; NP_114171.2; NM_031965.2. [Q8TF76-1]
DR   PDB; 2VUW; X-ray; 1.80 A; A=465-798.
DR   PDB; 2WB8; X-ray; 2.15 A; A=452-798.
DR   PDB; 3DLZ; X-ray; 1.85 A; A=465-798.
DR   PDB; 3E7V; X-ray; 2.00 A; A=471-798.
DR   PDB; 3F2N; X-ray; 1.80 A; A=465-798.
DR   PDB; 3FMD; X-ray; 2.00 A; A=470-798.
DR   PDB; 3IQ7; X-ray; 2.00 A; A=465-798.
DR   PDB; 4OUC; X-ray; 1.90 A; A=465-798.
DR   PDB; 4QTC; X-ray; 1.40 A; A=465-798.
DR   PDB; 5HTB; X-ray; 1.70 A; A=465-798.
DR   PDB; 5HTC; X-ray; 1.50 A; A=465-798.
DR   PDB; 6G34; X-ray; 1.76 A; A=465-798.
DR   PDB; 6G35; X-ray; 1.55 A; A=465-798.
DR   PDB; 6G36; X-ray; 1.46 A; A=465-798.
DR   PDB; 6G37; X-ray; 1.48 A; A=465-798.
DR   PDB; 6G38; X-ray; 1.47 A; A=465-798.
DR   PDB; 6G39; X-ray; 1.45 A; A=465-798.
DR   PDB; 6G3A; X-ray; 1.43 A; A=465-798.
DR   PDB; 6Z56; X-ray; 1.90 A; A=465-798.
DR   PDB; 6Z57; X-ray; 1.50 A; A=465-798.
DR   PDB; 6Z58; X-ray; 1.80 A; A=465-798.
DR   PDB; 6Z59; X-ray; 2.00 A; A=465-798.
DR   PDB; 6Z5A; X-ray; 1.55 A; A=465-798.
DR   PDB; 6Z5B; X-ray; 1.90 A; A=465-798.
DR   PDB; 6Z5C; X-ray; 1.75 A; A=465-798.
DR   PDB; 6Z5D; X-ray; 1.75 A; A=465-798.
DR   PDB; 6Z5E; X-ray; 1.50 A; A=465-798.
DR   PDB; 7AVQ; X-ray; 1.65 A; A=465-798.
DR   PDB; 7OPS; X-ray; 2.38 A; A=465-798.
DR   PDB; 7SQM; X-ray; 1.78 A; A=445-798.
DR   PDBsum; 2VUW; -.
DR   PDBsum; 2WB8; -.
DR   PDBsum; 3DLZ; -.
DR   PDBsum; 3E7V; -.
DR   PDBsum; 3F2N; -.
DR   PDBsum; 3FMD; -.
DR   PDBsum; 3IQ7; -.
DR   PDBsum; 4OUC; -.
DR   PDBsum; 4QTC; -.
DR   PDBsum; 5HTB; -.
DR   PDBsum; 5HTC; -.
DR   PDBsum; 6G34; -.
DR   PDBsum; 6G35; -.
DR   PDBsum; 6G36; -.
DR   PDBsum; 6G37; -.
DR   PDBsum; 6G38; -.
DR   PDBsum; 6G39; -.
DR   PDBsum; 6G3A; -.
DR   PDBsum; 6Z56; -.
DR   PDBsum; 6Z57; -.
DR   PDBsum; 6Z58; -.
DR   PDBsum; 6Z59; -.
DR   PDBsum; 6Z5A; -.
DR   PDBsum; 6Z5B; -.
DR   PDBsum; 6Z5C; -.
DR   PDBsum; 6Z5D; -.
DR   PDBsum; 6Z5E; -.
DR   PDBsum; 7AVQ; -.
DR   PDBsum; 7OPS; -.
DR   PDBsum; 7SQM; -.
DR   AlphaFoldDB; Q8TF76; -.
DR   SMR; Q8TF76; -.
DR   BioGRID; 123814; 63.
DR   DIP; DIP-38174N; -.
DR   IntAct; Q8TF76; 97.
DR   MINT; Q8TF76; -.
DR   STRING; 9606.ENSP00000325290; -.
DR   BindingDB; Q8TF76; -.
DR   ChEMBL; CHEMBL1075163; -.
DR   DrugBank; DB08004; (2S)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol.
DR   DrugBank; DB07698; 3-(3-aminophenyl)-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine.
DR   DrugBank; DB04604; 5-iodotubercidin.
DR   DrugBank; DB07995; H-89.
DR   GuidetoPHARMACOLOGY; 2028; -.
DR   GlyGen; Q8TF76; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8TF76; -.
DR   PhosphoSitePlus; Q8TF76; -.
DR   BioMuta; HASPIN; -.
DR   DMDM; 296439330; -.
DR   EPD; Q8TF76; -.
DR   jPOST; Q8TF76; -.
DR   MassIVE; Q8TF76; -.
DR   MaxQB; Q8TF76; -.
DR   PaxDb; Q8TF76; -.
DR   PeptideAtlas; Q8TF76; -.
DR   PRIDE; Q8TF76; -.
DR   ProteomicsDB; 74576; -. [Q8TF76-1]
DR   ProteomicsDB; 74577; -. [Q8TF76-2]
DR   Antibodypedia; 23135; 154 antibodies from 23 providers.
DR   DNASU; 83903; -.
DR   Ensembl; ENST00000325418.5; ENSP00000325290.4; ENSG00000177602.5. [Q8TF76-1]
DR   GeneID; 83903; -.
DR   KEGG; hsa:83903; -.
DR   MANE-Select; ENST00000325418.5; ENSP00000325290.4; NM_031965.2; NP_114171.2.
DR   UCSC; uc002fwp.4; human. [Q8TF76-1]
DR   CTD; 83903; -.
DR   DisGeNET; 83903; -.
DR   GeneCards; HASPIN; -.
DR   HGNC; HGNC:19682; HASPIN.
DR   HPA; ENSG00000177602; Tissue enhanced (bone marrow, lymphoid tissue, testis).
DR   MIM; 609240; gene.
DR   neXtProt; NX_Q8TF76; -.
DR   OpenTargets; ENSG00000177602; -.
DR   PharmGKB; PA134909705; -.
DR   VEuPathDB; HostDB:ENSG00000177602; -.
DR   eggNOG; KOG2464; Eukaryota.
DR   GeneTree; ENSGT00390000013015; -.
DR   HOGENOM; CLU_355235_0_0_1; -.
DR   InParanoid; Q8TF76; -.
DR   OMA; LCQHSLF; -.
DR   PhylomeDB; Q8TF76; -.
DR   TreeFam; TF313895; -.
DR   PathwayCommons; Q8TF76; -.
DR   SignaLink; Q8TF76; -.
DR   SIGNOR; Q8TF76; -.
DR   BioGRID-ORCS; 83903; 74 hits in 1117 CRISPR screens.
DR   EvolutionaryTrace; Q8TF76; -.
DR   GeneWiki; GSG2; -.
DR   GenomeRNAi; 83903; -.
DR   Pharos; Q8TF76; Tchem.
DR   PRO; PR:Q8TF76; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q8TF76; protein.
DR   Bgee; ENSG00000177602; Expressed in pancreatic ductal cell and 102 other tissues.
DR   Genevisible; Q8TF76; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0072354; F:histone kinase activity (H3-T3 specific); IMP:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0000278; P:mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0007064; P:mitotic sister chromatid cohesion; IMP:UniProtKB.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0071459; P:protein localization to chromosome, centromeric region; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   IDEAL; IID00574; -.
DR   InterPro; IPR024604; GSG2_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   SMART; SM01331; DUF3635; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Chromatin regulator; Chromosome; Cytoplasm; Cytoskeleton; Kinase;
KW   Magnesium; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..798
FT                   /note="Serine/threonine-protein kinase haspin"
FT                   /id="PRO_0000085989"
FT   DOMAIN          484..798
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000305"
FT   REGION          1..110
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          275..350
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        40..57
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        304..350
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        649
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         490..498
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         511
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         606..611
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19918057,
FT                   ECO:0007744|PDB:3DLZ"
FT   BINDING         649..654
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19918057,
FT                   ECO:0007744|PDB:3DLZ"
FT   BINDING         687..689
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19918057"
FT   MOD_RES         58
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         93
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:21658950,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         97
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         143
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:21658950"
FT   MOD_RES         147
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         314
FT                   /note="Q -> H (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_050671"
FT   VAR_SEQ         315..798
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_050672"
FT   VARIANT         76
FT                   /note="V -> E (in dbSNP:rs11653889)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040540"
FT   VARIANT         82
FT                   /note="R -> C (in dbSNP:rs9907144)"
FT                   /evidence="ECO:0000269|PubMed:11311556,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040541"
FT   VARIANT         145
FT                   /note="R -> H (in dbSNP:rs55991903)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040542"
FT   VARIANT         204
FT                   /note="G -> D (in dbSNP:rs220462)"
FT                   /evidence="ECO:0000269|PubMed:11311556,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_027405"
FT   VARIANT         283
FT                   /note="G -> S (in dbSNP:rs56224301)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040543"
FT   VARIANT         301
FT                   /note="Q -> L (in dbSNP:rs55649477)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040544"
FT   VARIANT         328
FT                   /note="I -> T (in dbSNP:rs220461)"
FT                   /evidence="ECO:0000269|PubMed:11311556,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_027406"
FT   VARIANT         378
FT                   /note="V -> A (in dbSNP:rs3809806)"
FT                   /evidence="ECO:0000269|PubMed:11311556,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_027407"
FT   VARIANT         422
FT                   /note="N -> D (in dbSNP:rs7223226)"
FT                   /id="VAR_027408"
FT   VARIANT         706
FT                   /note="M -> V (in dbSNP:rs56134695)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040545"
FT   MUTAGEN         492
FT                   /note="E->A: Markedly reduced affinity for histone H3 and
FT                   reduced histone H3 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19918049"
FT   MUTAGEN         511
FT                   /note="K->A: Strongly reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:19918057"
FT   MUTAGEN         651
FT                   /note="H->A: Strongly reduced enzyme activity, markedly
FT                   reduced affinity for histone H3."
FT                   /evidence="ECO:0000269|PubMed:19918049,
FT                   ECO:0000269|PubMed:19918057"
FT   MUTAGEN         707
FT                   /note="D->L: Markedly reduced affinity for histone H3 and
FT                   reduced histone H3 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19918049"
FT   MUTAGEN         709
FT                   /note="D->N: Markedly reduced affinity for histone H3 and
FT                   reduced histone H3 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19918049"
FT   MUTAGEN         713
FT                   /note="G->F: Markedly reduced affinity for histone H3 and
FT                   reduced histone H3 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19918049"
FT   MUTAGEN         716
FT                   /note="D->L: Markedly reduced histone H3 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19918049"
FT   CONFLICT        273
FT                   /note="R -> S (in Ref. 4; BAB71255)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339
FT                   /note="K -> E (in Ref. 6; AAH47457)"
FT                   /evidence="ECO:0000305"
FT   HELIX           454..466
FT                   /evidence="ECO:0007829|PDB:7SQM"
FT   HELIX           475..478
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           481..485
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          488..493
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          496..503
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          506..516
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          518..521
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           529..544
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           545..547
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          549..552
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          554..556
FT                   /evidence="ECO:0007829|PDB:3F2N"
FT   STRAND          559..568
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           571..583
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          599..606
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   TURN            612..618
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           622..643
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           652..654
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          655..659
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          663..669
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          672..677
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          681..685
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          692..695
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          698..700
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           709..711
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           717..729
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           739..754
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          758..760
FT                   /evidence="ECO:0007829|PDB:7SQM"
FT   HELIX           765..780
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           781..783
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   STRAND          784..786
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           787..793
FT                   /evidence="ECO:0007829|PDB:4QTC"
FT   HELIX           795..797
FT                   /evidence="ECO:0007829|PDB:4QTC"
SQ   SEQUENCE   798 AA;  88495 MW;  E0EDF8F0C58ADA31 CRC64;
     MAASLPGPGS RLFRTYGAAD GRRQRRPGRE AAQWFPPQDR RRFFNSSGSS DASIGDPSQS
     DDPDDPDDPD FPGSPVRRRR RRPGGRVPKD RPSLTVTPKR WKLRARPSLT VTPRRLGLRA
     RPPQKCSTPC GPLRLPPFPS RDSGRLSPDL SVCGQPRDGD ELGISASLFS SLASPCPGSP
     TPRDSVISIG TSACLVAASA VPSGLHLPEV SLDRASLPCS QEEATGGAKD TRMVHQTRAS
     LRSVLFGLMN SGTPEDSEFR ADGKNMRESC CKRKLVVGNG PEGPGLSSTG KRRATGQDSC
     QERGLQEAVR REHQEASVPK GRIVPRGIDR LERTRSSRKS KHQEATETSL LHSHRFKKGQ
     KLGKDSFPTQ DLTPLQNVCF WTKTRASFSF HKKKIVTDVS EVCSIYTTAT SLSGSLLSEC
     SNRPVMNRTS GAPSSWHSSS MYLLSPLNTL SISNKKASDA EKVYGECSQK GPVPFSHCLP
     TEKLQRCEKI GEGVFGEVFQ TIADHTPVAI KIIAIEGPDL VNGSHQKTFE EILPEIIISK
     ELSLLSGEVC NRTEGFIGLN SVHCVQGSYP PLLLKAWDHY NSTKGSANDR PDFFKDDQLF
     IVLEFEFGGI DLEQMRTKLS SLATAKSILH QLTASLAVAE ASLRFEHRDL HWGNVLLKKT
     SLKKLHYTLN GKSSTIPSCG LQVSIIDYTL SRLERDGIVV FCDVSMDEDL FTGDGDYQFD
     IYRLMKKENN NRWGEYHPYS NVLWLHYLTD KMLKQMTFKT KCNTPAMKQI KRKIQEFHRT
     MLNFSSATDL LCQHSLFK
//
